未登录

I

Ivan Babić

cellarisbio

H指数:22

被引数:2,665

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Real-Time Temperature Series MICRO-TAG Cell Target Engagement Assay Using Applied Biosystems QuantStudioTM System

基于Applied Biosystems QuantStudioTM系统的实时温度序列微型靶细胞结合分析

SLAS Technology

IF3.7

2026-05-200

OAAI

MICRO-TAG enzyme complementation enables quantification of cellular drug-target engagement in temperature series

MICRO-TAG酶互补技术能够实现对细胞药物-靶点结合在温度系列中的定量分析

IF2.7

2025-11-220

OAAI

Impact of preoperative conization on treatment outcomes in cervical cancer patients undergoing abdominal radical hysterectomy

腹式根治性子宫切除术患者中，术前锥形切除术对治疗结果的影响

BULLETIN DU CANCER

IF0.8

2025-10-010

PRE

Evaluation of UCP1162, a potent propargyl-linked inhibitor of dihydrofolate reductase with potential application to cancer and autoimmune disease

BIOCHEMICAL PHARMACOLOGY

IF5.6

2024-12-010

PRE

A phase 1 dose escalation of pritumumab in patients with refractory or recurrent gliomas or brain metastases

NEURO-ONCOLOGY ADVANCES

IF4.1

2024-09-300

OAAI

R9: A novel NuRD complex inhibitor for targeted therapy in triple negative breast cancer (TNBC)

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Probing monomer - dimer and conformational transitions of PLK1 using catalytic and polo-box domain inhibitors

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Novel Pan-RAS inhibitor ADT-007: A unique mechanism of antitumor selectivity in pancreatic and colorectal carcinoma models

CANCER RESEARCH

IF16.6

2024-03-220

PRE

MICRO-TAG: A novel fluorescence-based real-time cellular target engagement platform for drug discovery

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Atlas of therapeutic targets: Evolution of druggable proteome

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Unexpected role of the NuRD component, Chd4, in Foxp3+Treg cells and its relevance to tumor immunotherapy

CANCER RESEARCH

IF16.6

2024-03-220

PRE

MiRNA-mRNA integrative analysis reveals epigenetically regulated and prognostic miR-103a with a role in migration and invasion of carboplatin-resistant ovarian cancer cells that acquired mesenchymal-like phenotype

BIOMEDICINE & PHARMACOTHERAPY

IF7.5

2023-10-013

OAAI

ADT-030, a novel dual-acting RAS and β-catenin inhibitor with robust antitumor activity

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Real-time cellular target engagement and protein quantification for drug discovery

CANCER RESEARCH

IF16.6

2023-04-040

PRE

ADT-007 binds RAS and inhibits RAS signaling

CANCER RESEARCH

IF16.6

2023-04-041

PRE

A Role for Polypyrimidine Tract Binding Protein in the Establishment of Focal Adhesions

MOLECULAR AND CELLULAR BIOLOGY

IF2.7

2023-03-2131

OAAI

IRE1α and IGF signaling predict resistance to an endoplasmic reticulum stress-inducing drug in glioblastoma cells

SCIENTIFIC REPORTS

IF3.9

2020-05-2016

OAAI

Allosteric inhibitor of β-catenin selectively targets oncogenic Wnt signaling in colon cancer

SCIENTIFIC REPORTS

IF3.9

2020-05-1518

OAAI

Pritumumab mAb binds cell surface expressed vimentin on pancreatic cancer cells and inhibits tumor growth

CANCER RESEARCH

IF16.6

2018-07-011

PRE

Cellular target engagement: a new paradigm in drug discovery

细胞靶标参与: 药物发现的新范式

FUTURE MEDICINAL CHEMISTRY

IF3.4

2018-06-297

PREAI